Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,822 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,088 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01631279 | A Dose Escalation Trial of PR610 Treating Patients With Solid Tumors | terminated | Phase 1 / Phase 2 | 33 | Proacta, IncorporatedINDUSTRY | 2 | Jun 16, 2014 | clinicaltrials |
| NCT00729833 | Study Of CP-751,871 In Combination With Sunitinib In Patients With Advanced Solid Tumors | terminated | Phase 1 | 45 | PfizerINDUSTRY | 1 | Jun 9, 2014 | clinicaltrials |
| NCT00003009 |
| Inhaled Interleukin-2 in Treating Patients With Metastatic or Unresectable Cancer |
| terminated |
| Phase 1 |
| 16 |
| University of Southern CaliforniaOTHER |
| 1 |
| May 22, 2014 |
| clinicaltrials |
| NCT01581060 | Phase I/II Dose-escalation Study to Investigate Safety and Pharmacokinetics/ Pharmacodynamics of WX-554 in Patients With Solid Tumours | terminated | Phase 1 / Phase 2 | 41 | Heidelberg Pharma AGINDUSTRY | 1 | May 16, 2014 | clinicaltrials |
| NCT01859351 | Phase I Study of WX-037 Alone and in Combination With WX-554 in Solid Tumours | terminated | Phase 1 | 13 | Heidelberg Pharma AGINDUSTRY | 1 | May 16, 2014 | clinicaltrials |
| NCT01018836 | Riluzole and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases | terminated | Phase 1 | 9 | Rutgers, The State University of New JerseyOTHER | 1 | May 2, 2014 | clinicaltrials |
| NCT00933985 | Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia | terminated | Phase 1 | 22 | National Cancer Institute (NCI)NIH | 2 | May 1, 2014 | clinicaltrials |
| NCT01233505 | Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors | terminated | Phase 1 | 16 | National Cancer Institute (NCI)NIH | 1 | Apr 2, 2014 | clinicaltrials |
| NCT00404521 | A Phase I Study of PM02734 in Subjects With Advanced Malignant Solid Tumors | terminated | Phase 1 | 56 | PharmaMarINDUSTRY | 1 | Mar 26, 2014 | clinicaltrials |
| NCT01641575 | A Dose Ascending Study of Gemcitabine Elaidate (CO-101) in Combination With Cisplatin | terminated | Phase 1 | 8 | Clovis Oncology, Inc.INDUSTRY | 2 | Mar 11, 2014 | clinicaltrials |
| NCT01131364 | Combination Therapy of F16IL2 and Doxorubicin in Solid Tumour Patients | terminated | Phase 1 / Phase 2 | 29 | Philogen S.p.A.INDUSTRY | 1 | Feb 25, 2014 | clinicaltrials |
| NCT00096005 | Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas | terminated | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 1 | Feb 24, 2014 | clinicaltrials |
| NCT00101205 | Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma | terminated | Phase 1 | 40 | National Cancer Institute (NCI)NIH | 1 | Feb 24, 2014 | clinicaltrials |
| NCT00112684 | Alvocidib in Treating Patients With Locally Advanced or Metastatic Solid Tumors | terminated | Phase 1 | 25 | National Cancer Institute (NCI)NIH | 1 | Feb 24, 2014 | clinicaltrials |
| NCT00436579 | Sorafenib in Treating Patients With Advanced Solid Tumors | terminated | Phase 1 | 110 | National Cancer Institute (NCI)NIH | 1 | Feb 24, 2014 | clinicaltrials |
| NCT00701298 | Decitabine With or Without Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Solid Tumors | terminated | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Feb 24, 2014 | clinicaltrials |
| NCT00337376 | A Study of the mTOR Inhibitor Rapamycin (Rapamune, Sirolimus) in Combination With Abraxane in Advanced Solid Cancers | terminated | Phase 1 | 23 | Yale UniversityOTHER | 1 | Jan 14, 2014 | clinicaltrials |
| NCT00019708 | Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma | terminated | Phase 1 | 45 | National Cancer Institute (NCI)NIH | 1 | Dec 16, 2013 | clinicaltrials |
| NCT00070239 | Alvocidib in Treating Patients With Metastatic or Unresectable Refractory Solid Tumors or Hematologic Malignancies | terminated | Phase 1 | 100 | National Cancer Institute (NCI)NIH | 1 | Dec 16, 2013 | clinicaltrials |
| NCT00369200 | AFP464 in Treating Patients With Advanced Solid Tumors | terminated | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Dec 11, 2013 | clinicaltrials |
| NCT01496534 | Phase Ib Study of Gemcitabine Plus Cisplatin or Carboplatin Plus Dovitinib in Patients With Advanced Solid Tumors | terminated | Phase 1 | 14 | Matthew GalskyOTHER | 1 | Nov 27, 2013 | clinicaltrials |
| NCT01337544 | Haploidentical Stem Cell Transplantation and IL-15 NK Cell Infusion for Paediatric Refractory Solid Tumours(NK) | terminated | Phase 1 / Phase 2 | 6 | Hospital Infantil Universitario Niño Jesús, Madrid, SpainOTHER | 1 | Nov 11, 2013 | clinicaltrials |
| NCT00689065 | Safety Study of CALAA-01 to Treat Solid Tumor Cancers | terminated | Phase 1 | 24 | Calando PharmaceuticalsINDUSTRY | 1 | Nov 1, 2013 | clinicaltrials |
| NCT01110083 | First-in-Man, Dose-escalation Trial of c-Met Kinase Inhibitor EMD 1204831 in Subjects With Advanced Solid Tumors | terminated | Phase 1 | 38 | EMD SeronoINDUSTRY | 1 | Oct 22, 2013 | clinicaltrials |
| NCT01159301 | Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia | terminated | Phase 1 | 44 | National Cancer Institute (NCI)NIH | 1 | Sep 19, 2013 | clinicaltrials |
| NCT00550199 | LBH589 and Gemcitabine in the Treatment of Solid Tumors | terminated | Phase 1 | 17 | SCRI Development Innovations, LLCOTHER | 1 | Aug 19, 2013 | clinicaltrials |
| NCT00012194 | 7-hydroxystaurosporine and Cisplatin in Treating Patients With Advanced Malignant Solid Tumors | terminated | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Jul 9, 2013 | clinicaltrials |
| NCT00009958 | Vaccine Therapy With or Without Sargramostim in Treating Patients With Cancer | terminated | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | May 16, 2013 | clinicaltrials |
| NCT00354185 | PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma | terminated | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 1 | May 16, 2013 | clinicaltrials |
| NCT00558727 | Study of RH-1 in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma | terminated | Phase 1 | 12 | Spectrum Pharmaceuticals, IncINDUSTRY | 1 | May 10, 2013 | clinicaltrials |
| NCT01602627 | Hsp90 Inhibitor AUY922 in Treating Older Patients With Advanced Solid Malignancies | terminated | Phase 1 | 2 | Dale Shepard, MD, PhDOTHER | 1 | Feb 7, 2013 | clinicaltrials |
| NCT00066625 | Oxaliplatin and Bortezomib in Treating Patients With Advanced Cancer | terminated | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Feb 1, 2013 | clinicaltrials |
| NCT00010205 | Benzoylphenylurea in Treating Patients With Advanced Cancer | terminated | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Jan 25, 2013 | clinicaltrials |
| NCT00060112 | Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma | terminated | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | Jan 25, 2013 | clinicaltrials |
| NCT00030693 | Vaccine Therapy in Treating Patients With Metastatic Solid Tumors | terminated | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00049088 | Bortezomib and Docetaxel in Treating Patients With Advanced Solid Tumors | terminated | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00086970 | Ifosfamide With or Without O(6)-Benzylguanine in Treating Patients With Unresectable, Metastatic Solid Tumors | terminated | Phase 1 | 32 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00028561 | BMS-247550 Plus Carboplatin in Treating Patients With Recurrent or Refractory Solid Tumors | terminated | Phase 1 | 45 | National Cancer Institute (NCI)NIH | 1 | Jan 17, 2013 | clinicaltrials |
| NCT00101244 | SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's Lymphoma | terminated | Phase 1 | 31 | National Cancer Institute (NCI)NIH | 1 | Jan 14, 2013 | clinicaltrials |
| NCT00086983 | Rebeccamycin Analog and Oxaliplatin in Treating Patients With Refractory Solid Tumors | terminated | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | Jan 10, 2013 | clinicaltrials |
| NCT00089089 | Decitabine in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas | terminated | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | Jan 7, 2013 | clinicaltrials |
| NCT01416623 | A Phase I Study of Henatinib in Patients With Advanced Solid Malignancies | terminated | Phase 1 | 44 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Dec 21, 2012 | clinicaltrials |
| NCT00424645 | Voraxaze for Delayed Methotrexate Clearance | terminated | Phase 1 / Phase 2 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 6, 2012 | clinicaltrials |
| NCT00512798 | Bortezomib and Temozolomide in Treating Patients With Advanced Refractory Solid Tumors or Melanoma | terminated | Phase 1 / Phase 2 | 47 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Oct 2, 2012 | clinicaltrials |
| NCT01286974 | A Pharmacokinetic Study to Access How the Body Absorbs and Removes Linifanib in Male Patients With Advanced Solid Tumors. | terminated | Phase 1 | 3 | AbbottINDUSTRY | 1 | Sep 21, 2012 | clinicaltrials |
| NCT01016327 | Study of NMS-1116354 in Solid Tumors | terminated | Phase 1 | 15 | Nerviano Medical SciencesINDUSTRY | 1 | Sep 7, 2012 | clinicaltrials |
| NCT00511017 | Doxercalciferol in Recurrent Pediatric Solid Tumors | terminated | Phase 1 | 1 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 31, 2012 | clinicaltrials |
| NCT01226901 | A Phase I Study of MK-4827 for Treatment of Solid Tumors (MK-4827-005) | terminated | Phase 1 | 3 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 28, 2012 | clinicaltrials |
| NCT01147029 | GSAO in Treating Patients With Advanced Solid Tumors That Have Not Responded to Therapy | terminated | Phase 1 | 35 | Cancer Research UKOTHER | 1 | May 1, 2012 | clinicaltrials |
Data updated 22 days agoSource updated Jun 16, 2014source: clinicaltrials